Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Rang in Aktien #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Aktienkurs
$0.38
Zuletzt synchronisiert: 2023-09-01
Marktkapitalisierung
$677.16K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Aceragen, Inc. (ACGN)

Kategorie

Kursverlauf für Aceragen, Inc. (ACGN)
Höchster Schlusskurs: $0.38 am 2023-09-01

Niedrigster Schlusskurs: $64.33K am 1996-01-01
Kursverlauf der Aktie von Aceragen, Inc. von 1996 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 -92.15%
2022 -56.36%
2021 -85.30%
2020 156.42%
2019 -62.29%
2018 -71.51%
2017 25.28%
2016 -54.63%
2015 -10.86%
2014 28.19%
2013 290.03%
2012 -27.35%
2011 -57.65%
2010 -48.14%
2009 -35.84%
2008 -34.66%
2007 126.13%
2006 11.76%
2005 25.16%
2004 -60.39%
2003 51.06%
2002 -54.68%
2001 218.06%
2000 -48.13%
1999 -40.76%
1998 -61.27%
1997 -85.90%
1996 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$517.18 32.51%
US
$857.76 31.47%
NL
$728.05 6.60%
CH
$1.07K -6.40%
KR
$254.79 12.56%
BE